Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
NCT03695055 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2018-10-03
Summary
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
Conditions
- High-risk Aggressive Lymphoma After Auto-HSCT
Interventions
- DRUG
-
Maintenance therapy post-HSCT
Rituximab vs DPP/DCEP-G vs observation
Sponsors & Collaborators
-
Fujian Medical University
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 14 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2020-01-31
- Completion
- 2023-01-31
Countries
- China
Study Locations
More Related Trials
-
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
NCT03624530 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839 ·Status: RECRUITING ·Phase: PHASE1
-
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
NCT03150134 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
NCT02957032 ·Status: TERMINATED ·Phase: PHASE1
-
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
NCT05124288 ·Status: RECRUITING
-
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
NCT02059720 ·Status: UNKNOWN ·Phase: PHASE3
-
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
NCT03121079 ·Status: WITHDRAWN ·Phase: NA
-
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML
NCT03620955 ·Status: UNKNOWN
-
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
NCT06130579 ·Status: RECRUITING ·Phase: PHASE2
-
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
NCT05382390 ·Status: RECRUITING ·Phase: PHASE3
-
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
NCT05991973 ·Status: COMPLETED ·Phase: PHASE2
-
Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT
NCT05604755 ·Status: WITHDRAWN ·Phase: PHASE2
-
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
NCT03515512 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
NCT05224661 ·Status: ACTIVE_NOT_RECRUITING
-
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
NCT06427330 ·Status: RECRUITING ·Phase: PHASE2
-
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244 ·Status: RECRUITING
-
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
NCT07319793 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT02888522 ·Status: UNKNOWN
-
Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS
NCT04166929 ·Status: TERMINATED ·Phase: PHASE2
-
Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML
NCT01496547 ·Status: COMPLETED ·Phase: PHASE2
-
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
NCT06754540 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT
NCT02850822 ·Status: UNKNOWN
-
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
NCT03297528 ·Status: UNKNOWN ·Phase: PHASE2
-
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
NCT03462095 ·Status: UNKNOWN ·Phase: NA